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ABSTRACT 
Objectives: The aim of this study was to review and analyze the current literature for 
controlled studies comparing drug-eluting stents (DES) versus bare-metal stents (BMS) for 
treatment of saphenous vein graft (SVG) stenoses. 
 
Background: Saphenous vein grafts develop an aggressive atherosclerotic process and the 
efficacy of DES in treating SVG lesions has not been convincingly demonstrated.   
 
Methods: We searched several scientific databases and conference proceedings up to 
February 11, 2010 for controlled studies comparing target vessel revascularization (TVR) 
between DES and BMS. Summary odds ratios (OR) for the primary endpoint TVR and 
secondary endpoints infarction, stent thrombosis and death were calculated using random-
effect models. 
 
Results: A total of 24 studies (3 randomized controlled trials RCT) involving 6391 (202 in 
RCT) patients were included. The need for target vessel revascularization in the DES group 
was lower compared to BMS for the 3 RCT (OR 0.51 [0.27 - 0.96]; p=0.037) and for 
observational studies (0.64 [0.48 - 0.85]; p=0.002). There was no significant difference in the 
risk for myocardial infarction in the RCT (OR 1.25 [0.22 - 6.99]; p=0.250) nor in the 
observational studies (0.75 [0.53 - 1.06]; p= 0.107). The risk for stent thrombosis was found 
to be non-different in the RCT (OR 0.78 [0.03 - 21.73], p=0.885) while it was in favor of DES 
in the observational studies (0.49 [0.25 - 0.94]; p=0.0324). The mortality was not significantly 
different between DES and BMS in the RCT’s (OR 2.2 [0.17 – 29.5]; p=0.546) while the 
observation studies showed a decreased mortality in the DES group (OR 0.66 [0.54 - 0.81]; p 
< 0.0001). 
.   
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Conclusion: DES decrease TVR rate in treatment of SVG stenosis. No differences in 
reinfarction rate, stent thrombosis or mortality was found between the DES and BMS groups 
in the RCT’s while the observational data showed lower risk for stent thrombosis and death in 
the DES group which may be a result of selection bias. 
 
Key words: saphenous vein graft, SVG, BMS, DES, meta-analysis. 
 
Abbreviations and Acronyms 
BMS = bare metal stent(s) 
CABG = coronary artery bypass graft  
CAD = coronary artery disease 
DES = drug eluting stent(s) 
PCI = percutaneous coronary intervention 
RCT = randomized controlled trial(s) 
ST = stent thrombosis 
SVG = saphenous vein graft 
MI = myocardial infarction 
TVR = target vessel revascularization 
 
Condensed Abstract 
Interventions in saphenous vein grafts (SVG) accounts for about 15% of all percutaneous 
coronary interventions and  the number of  such procedures is likely to increase in the future. 
Little is known about the benefit and risk of drug-eluting stent (DES) in this setting; DES 
have not been specifically approved for SVG in the U.S. but are used increasingly in an “off-
label” fashion.  Our meta-analysis of 3 randomized clinical trials and 21 non-randomized 
controlled studies indicates a reduction of need for target-vessel revascularization with similar 
outcomes regarding stent thrombosis, myocardial infarction and mortality.   
However, this analysis is based on sparse intermediate term data and more long-term data is 
needed to support use of DES in saphenous vein grafts. 
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Background  
Coronary artery bypass graft (CABG) is among the most frequently performed surgical 
procedures in the U.S. and Europe and a mainstay of therapy for coronary artery disease 
(CAD). Saphenous vein grafts are the most common type of the grafts used in coronary by-
pass surgery. SVG interventions currently account for approximately 10% of total PCI 
procedures annually in the United States.(1) This number is likely to increase in the near 
future since there is emerging evidence that even lower degree stenoses (30-60%) may profit 
from stent implantations;(2) very much in contrast to stenoses in native vessels where 
increasing data suggest that only hemodynamically significant higher degree stenoses should 
be treated.(3) The natural and post-interventional biological behaviour of saphenous vein 
grafts clearly differs from native vessels, they are at higher risk for restenosis.(4) While BMS 
are currently the gold standard for SVG stenosis, the off-label use of DES has shown 
promising results in several observational studies while there is a dearth of adequately 
powered randomized trials. (5-7) These trials have produced conflicting results but each trial 
lacks sufficient statistical power to detect a difference in clinical endpoints 
The aim of this meta-analysis was to review and analyze the current literature for controlled 
randomized and non-randomized studies comparing drug-eluting stents (DES) versus bare-
metal stents (BMS) for treatment of SVG stenoses.  
 
 
Methods 
Eligibility criteria 
 Planning and study design was done by two authors (HSG, PM) including creation of an 
electronic database with variables of interest (Microsoft Excel). Primary and secondary 
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endpoints, variables of interest and search strategy (databases, sources for unpublished data) 
were defined in a strategy outline which can be obtained from study authors on request. 
We included controlled (randomized and non-randomized) studies that compared DES and 
BMS (with and without the use of protection devices) in patients with saphenous vein graft 
(SVG) stenosis. The outcome of primary interest was TVR and the secondary outcomes were 
myocardial infarction, stent thrombosis or death. Because we expected paucity of data, 
observational studies were not excluded a-priori even though the primary focus was on RCT.  
We searched EMBASE, PubMed, MEDLINE, the Cochrane Central Register of Controlled 
Trials, International Pharmaceutical Abstracts database, ISI Web of Science, and google 
scholar from 2002 through February 11, 2010. In addition, abstract lists and conference 
proceedings from the 2006 to 2009 scientific meetings of the American College of 
Cardiology, and the 2006 to 2009 meetings of the European Society of Cardiology, the 
Transcatheter Cardiovascular Therapeutics, and the American Heart Association were 
included. We also considered published review articles, editorials, and internet-based sources 
of information (www.tctmd.com, www.theheart.org) to assess potential information on 
studies of interest.. 
Search strategy for MEDLINE was: “saphenous vein graft” [All Fields] AND (“bare-metal 
stent” [All Fields] OR “drug-eluting stent” [All Fields] OR “paclitaxel-eluting stent”[All 
Fields] OR “sirolimus-eluting stent” ”[All Fields] OR “everolimus-eluting stent” [All Fields] 
OR zatarolimus-eluting stent”  [All Fields] OR “stents” [MeSH Terms] ). “No restriction on 
subheadings was applied. Similar but adapted search terms were used for the other literature 
databases.  
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Reference lists of selected articles were reviewed for other potentially relevant citations. 
Authors of selected studies were contacted to obtain further information. All trials comparing 
DES versus BMS in patients with SVG were included in this analysis.  
 
Study selection 
In a two-step selection process, two investigators (HSG and PM) independently reviewed the 
titles and abstracts of all citations to identify all potentially relevant studies. In a second step 
the corresponding publications were reviewed in full text by the same two investigators to 
assess if studies were meeting the following inclusion criteria: direct comparison of DES vs. 
BMS, controlled trial including a BMS control group, and reporting clinical outcomes (TVR, 
death, ST or MI; Figure 1). Reviewers were not blinded to study authors or outcomes. Final 
inclusion of studies was based on agreement of both reviewers.  
 
Data extraction  
The relevant information from the articles including baseline clinical characteristics of the 
study population was extracted by two investigators (PM and UT).  
 
Data synthesis and analysis 
All analyses were performed on an intention-to-treat basis. Continuity correction was used 
when an event did not occur in one group.(8)We evaluated the presence of heterogeneity 
across trials with the Q and I2 statistics, an I2 value >25% was regarded as relevant 
heterogeneity. Observational studies and RCT were combined separately and pooled odds 
ratios (OR) of effect sizes for DES compared with BMS were estimated using a fixed-effects 
model with Mantel-Haenszel weights in case of low between study heterogeneity or random-
effect models with the DerSimonian-Laird approach in case of relevant study heterogeneity 
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(I2 >25%). Data are presented as OR point estimate with 95% confidence intervals within 
brackets.  
Weighted meta-analytical prevalence estimates for outcome in DES and BMS patients were 
calculated using the variance stabilising Freeman-Tukey double arcsine transformation with 
an  inverse variance  random effects model.(9)All analyses were performed with R version 
2.9.0(10) (packages “meta”, “metafor” and “rmeta”) and SAS, version 9.2 (SAS Institute, 
Cary, NC) (proc mixed).(11)  
 
Results 
A total of 196 articles were reviewed, and 24 studies including 6391 patients (202 in RCT)  
satisfied the predetermined strict inclusion criteria; among these, 3 were RCT (Figure 1). (5-
7,12) Table 1 summarizes the characteristics of the studies. The other 21 studies were 
observational .(13-32) 
Primary endpoint 
TVR: In the 3 RCT, TVR occurred in 22.3% [12.1 – 34.7%] of patients with DES and in 
36.3% [26.9-46.4%] of patients with BMS. The summary OR was 0.51 [0.27 - 0.96]; 
p=0.037; heterogeneity I2=16.2%; p=0.303; Figure 2) in favor of DES.  
The OR for the observational studies was 0.64 [0.48 - 0.85]; p=0.002; heterogeneity: I2=61.4 
%, p=0.0001).  
Secondary endpoints 
Myocardial infarction: In the 3 RCT, infarction occurred in 13.7% [7.0 – 21.7%] of patients 
after DES implantation compared to 11.1% [0.5 – 33.1%] after BMS implantation. The OR 
for RCT exclusively was 1.25 [0.22 - 6.99]; p=0.250; heterogeneity: I2=64.8%; p=0.058) 
(Figure 3). In the observation studies, the OR was found to be 0.75 [0.53 - 1.06]; p= 0.107; 
heterogeneity: I2= 32.8%; p=0.106).  
 
Running title: DES vs. BMS in SVG 
Pascal Meier et al.  9 of 20 
Stent thrombosis: In the 2 RCT reporting on this endpoint, the OR for DES compared to BMS 
was 0.78 (0.03 - 21.73, p=0.885; heterogeneity: I2= 68.2%; p=0.076) (Figure 4). The OR for 
the observational studies was in favor of DES (0.49 [0.25 - 0.94]; p=0.0324 ; heterogeneity: 
I2= 0%; p=0.794).   
 
Mortality: For the 3 RCT, the OR for mortality between DES and BMS was 2.2 (0.17 – 29.5; 
p=0.546; heterogeneity: I2=75.8%;p=0.019). For the observational studies, the OR for 
mortality for DES compared to BMS was 0.66 [0.54 - 0.81]; p < 0.0001; heterogeneity: 
I2=0%; p=0.641] (Figure 5).  
 
Discussion 
In this meta-analysis of 24 studies (3 RCT and 21 observational studies) including 6408 
patients, DES were superior to BMS with regard to TVR while no difference was found in 
risk for stent infarction or stent thrombosis in the RCT. The observational studies revealed a 
reduced risk for stent thrombosis and mortality risk for DES but these finding may be 
explained by selection bias.  
  
Saphenous vein graft stenting is an entity that has to be investigated specifically. SVG are 
different in many regards from arterial vessels. Media layers of the SVG are thinner than that 
of coronary arteries, and thus, is likely to be more susceptible to the mechanical damage 
caused by stents and balloon pressure. Media fracture has been associated with exaggerated 
neointimal response.(33) Usually, degenerated vein grafts stenoses are due to soft friable 
plaques without fibrous cap. Classical atherogenesis probably plays a minor role, 
hypothesized mechanisms are intimal thrombus that convents into fibrous plaque, change in 
wall stress (“arterialization” of the vein) and impairment of intrinsic vascular supply.(34,35) 
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Although restenosis rates are markedly higher in SVG compared with native vessels, 
classically, BMS is the treatment of choice for SVG stenoses(7) while this setting is regarded 
an off-label use for DES. However, DES are commonly used in various clinical settings to 
treat native coronary artery lesions and have been shown to reduce restenosis rates, especially 
in patients with higher risk for restenosis (diabetes mellitus, small vessels etc.). Saphenous 
vein graft stenting clearly represents a higher risk setting. Thus, DES are nowadays 
increasingly being used off-label to treat SVG stenoses, there are limited safety and efficacy 
data available in this setting. On the other hand, there have been even increased concerns and 
data suggesting that the effect of DES may be attenuated by the different biological properties 
of vein grafts or that DES may even be harmful.(12,33) 
 
 
While short term results from the RRISC trial appeared promising with late lumen loss, 
restenosis rates, and TVR significantly reduced at 6 months in patients treated with sirolimus-
eluting stents (SES), longer term results showed that patients with SES had higher mortality 
rates than their BMS counterparts and similar rates of TVR. (5,12). Recent observational data 
suggested also a late “catch-up” phenomenon regarding TVR with a clear benefit for DES in 
the first year but similar longer term results.(36) It seems plausible that, after the coating drug 
has completely eluted, the beneficial effect of DES compared to BMS decreases. Due to the 
different biological properties of saphenous vein grafts, this late “catch up” phenomenon may 
be more pronounced than in native vessels.  
 
Limitations  
The main limitation of this study is the small number of RCT available for inclusion. 
Furthermore, each of the 3 RCT was rather small. (5-7) The meta-analysis of the 
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observational studies are reflecting the “real-world” and further support the conclusion but 
observational data are of course prone to bias toward patient selection. (16)  
We have to acknowledge that even our pooled analysis is very limited in statistical power and 
the results showed only a borderline significance for TVR. On the other hand, the 
observational studies in this meta-analysis support that DES may be beneficial regarding TVR 
in SVG. Observational data are, of course, prone to bias due to non-random treatment 
allocation.  
Further, it must be noted that a majority of the studies had a short follow-up period (6-12 
months). It has also to be considered that two of the three included RCT, the RRISC and the 
SOS trial, used an angiographic primary endpoint. Better angiographic outcomes do not 
necessarily translate to better clinical outcomes and angiographic follow-up does not reflect 
the “real-world”. Thus, these two trials may overestimate the need for repeat TVR. 
 
Conclusion 
Our meta-analysis suggests that the use of DES is superior to the use BMS for treatment of 
SVG with regard to TVR but that there are no differences in safety endpoints such as 
infarction, stent thrombosis or infarction risk.  
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Figure Legends 
 
Figure 1 Flow chart depicting outline of the search and selection strategy 
DES=drug-eluting stent; BMS=bare metal stent;  SVG=saphenous vein graft. 
 
Figure 2 The Forest plot of odds ratios (OR) of target-vessel revascularization (TVR). Sizes 
of data markers are proportional to the weight of each study in the meta-analysis. Horizontal 
bars, 95% CI. Observational=observational, non-randomized controlled studies; DES=drug-
eluting stent; BMS=bare metal stent; RCT=randomized controlled trials. 
 
Figure 3 The Forest plot of odds ratios (OR) of myocardial infarction. Sizes of data markers 
are proportional to the weight of each study in the meta-analysis. Horizontal bars, 95% CI. 
Observational=observational, non-randomized controlled studies; DES=drug-eluting stent; 
BMS=bare metal stent; RCT=randomized controlled trials. 
 
Figure 4 The Forest plot of odds ratios (OR) of stent thrombosis (ST), stratified by study 
type. Sizes of data markers are proportional to the weight of each study in the meta-analysis. 
Horizontal bars, 95% CI. Observational=observational, non-randomized controlled studies; 
DES=drug-eluting stent; BMS=bare metal stent; RCT=randomized controlled trials. 
 
Figure 5 The Forest plot of odds ratios (OR) of mortality, stratified by study type. Sizes of 
data markers are proportional to the weight of each study in the meta-analysis. Horizontal 
bars, 95% CI. Observational=observational, non-randomized controlled studies; DES=drug-
eluting stent; BMS=bare metal stent; RCT=randomized controlled trials 
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Table 1: Characteristics of included studies      
Study N Stent Follow up (mts) Remarks Patient age 
(yrs) 
Graft age 
(yrs) 
Protection 
device (%)
Randomized controlled trials       
BASKET 13 BMS 18  71 na na 
34 DES 18 SES and PES 71 na na 
Delayed RRISC 37 BMS  median 32  72 12.6 na 
38 DES  median 30.5 SES 73 12.4 na 
SOS 39 BMS  median 18  67 12.0 56 
41 DES  median 18 PES 66 11.0 51 
       
Observational studies        
Ge et al. 89 BMS 6 na 67 9.2 22.5 
61 DES  na 67 9.7 31.1 
Lee et al. 84 BMS mean 9   69 na 15 
139 DES mean 10 211 SES; 78 PES 69 na 19 
Chu et al. 57 BMS 12  71 9.4 100 
48 DES 12 SES 69 10.1 100 
Hoffman et al. 60 BMS 6 (TLR)  67 na 52 
60 DES 6 (TLR) PES 67 na 64 
Wohrle et al. 26 BMS 12  70 9.1 0 
13 DES 12 PES 71 11.4 0 
Ellis et al. 175 BMS 12  69 9.8 25.1 
175 DES 12 SES 70 10.0 35.6 
Minutello et al. 50 BMS mean 20  69 na 48 
59 DES mean 21 SES 71 na 71.2 
Bansal et al. 72 BMS mean 33  65 na 27 
37 DES mean 34 95% SES; 5% PES 68 na 39 
Gioia et al. 119 BMS up to 23  70 11.0 na 
106 DES up to 23 106 SES; 48 PES 71 11.0 na 
Assali et al. 43 BMS 24  71 11.4 48 
68 DES 24 SES 70 10.8 38 
van Twisk et al. 128 BMS 48  69 na na 
122 DES 48 SES, PES 68  na 
Vignali et al. 288 BMS  median 13.7   71 10.7 na 
72 DES  median 13.8 na 75 9.0 na 
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Wilson et al. 281 BMS 9  na na na 
418 DES 9 243 SES, 171 PES na na na 
May et al. 176 BMS 12 (TLR)  69 na na 
201 DES 13 (TLR) na 69 na na 
Voudris et al. 40 BMS mean 22.5   na na na 
43 DES mean 22.6 90 % SES; 10% PES  na na na 
Moore et al. 173 BMS 12 (TLR)  67 na na 
171 DES 13 (TLR) SES,PES 69 na na 
Okabe et al. 344 BMS 12  70 na 21 
138 DES 12 17 SES; 66 PES 70 na 26 
Applegate et al. 74 BMS 24  69 na 47 
74 DES 24 67 SES; 7 PES 69 na 53 
Shishehbor et al.(13) 349 BMS 35  69 na 30 
217 DES 35 na 70 na 56 
Lozano et al.(32) 114 BMS 30  71 121 na 
98 DES 30 na 66 108 na 
Brodie et al.(36) 343 BMS 9  69 na 33.7 
785 DES 9 59% SES, 38% PES, 
3% both 
68 na 37.3 
BMS: bare-metal stent; DES: drug-eluting stent; na: not available; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent;  
TLR: target lesion revascularization; TVR: target vessel revascularization.     
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